Fig. 3From: Arbaclofen in fragile X syndrome: results of phase 3 trialsBaseline and end-of-treatment scores (a) and change in scores (b) for the primary outcome measure, the ABC-FX-Social Avoidance subscore, in child study for placebo and highest dose (10Â mg TID) arbaclofen groupsBack to article page